Copy Section


{{moment(articledata.cdate)}} @{{" ","")}} comment

A Georgia-based %Healthcare company is turning heads on Wednesday morning after it was announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (%DAPA) for distribution by the Defense Logistics Agency (%DLA).

Shares of %SonomaPharmaceuticals ($SNOA ) soaring during Wednesday’s premarket as shares of this micro cap are currently bid up at $2.04/share (+70.00% implied open for sellers) at the time of writing. The release went on to say that the “DAPA enables our partner, EMC Pharma, to enter into distribution agreements for Microcyn® Rx products with federal customers.”

Sonoma Pharmaceuticals Inc is a specialty %Pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

More from @{{" ", "") }}